These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1362277)

  • 1. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia.
    Wolkowitz OM; Turetsky N; Reus VI; Hargreaves WA
    Psychopharmacol Bull; 1992; 28(3):291-5. PubMed ID: 1362277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia.
    Pato CN; Wolkowitz OM; Rapaport M; Schulz SC; Pickar D
    Psychopharmacol Bull; 1989; 25(2):263-6. PubMed ID: 2574897
    [No Abstract]   [Full Text] [Related]  

  • 4. [Schizophrenia combination therapy with neuroleptics and benzodiazepines].
    Ruzikowska A
    Psychiatr Pol; 1996; 30(1):55-64. PubMed ID: 8722239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzodiazepines in schizophrenia.
    Stimmel GL
    Pharmacotherapy; 1996; 16(6 Pt 2):148S-151S; discussion 166S-168S. PubMed ID: 8947998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychopharmacological treatment of treatment-resistant schizophrenia].
    Lublin HK
    Ugeskr Laeger; 1997 Nov; 159(48):7128-33. PubMed ID: 9417718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal.
    Wolkowitz OM; Pickar D
    Am J Psychiatry; 1991 Jun; 148(6):714-26. PubMed ID: 1674645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study.
    Csernansky JG; Lombrozo L; Gulevich GD; Hollister LE
    J Clin Psychopharmacol; 1984 Dec; 4(6):349-52. PubMed ID: 6150950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practical aspects of drug resistance in schizophrenia].
    Jarema M; Kucińska M
    Psychiatr Pol; 2000; 34(5):721-40. PubMed ID: 11202015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benzodiazepines and schizophrenia, a review of the literature].
    Gaillard R; Ouanas A; Spadone C; Llorca PM; Lôo H; Baylé FJ
    Encephale; 2006; 32(6 Pt 1):1003-10. PubMed ID: 17372546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia.
    Mallinger JB; Lamberti SJ
    J Ment Health Policy Econ; 2007 Mar; 10(1):15-22. PubMed ID: 17417044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone: an analysis of the first three years in general use.
    Gutierrez-Esteinou R; Grebb JA
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
    Fitzgerald PB
    Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzodiazepines (BZ) for the management of psychosis.
    Easton MS; Janicak PG
    Psychiatr Med; 1991; 9(1):25-36. PubMed ID: 1673257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in concomitant medication with benzodiazepines or antidepressants in first-break schizophrenic patients treated with antipsychotic medication.
    Rijcken CA; Knegtering H; Bruggeman R; Tobi H; de Jong-van den Berg LT
    Psychiatry Res; 2005 Apr; 134(2):143-50. PubMed ID: 15840415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.
    Lerner V; Libov I; Kotler M; Strous RD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):89-98. PubMed ID: 14687862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.